| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1399-0012.2006.00597.X |
| P698 | PubMed publication ID | 17100698 |
| P50 | author | Arianeb Mehrabi | Q67168816 |
| P2093 | author name string | Martin Zeier | |
| Jan Schmidt | |||
| Christian Morath | |||
| Vedat Schwenger | |||
| Walter Muranyi | |||
| Jörg Beimler | |||
| P2860 | cites work | Effect of mycophenolate mofetil on the in vivo infiltration of lymphocytes in the rat remnant kidney | Q47940592 |
| A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1 | Q57704207 | ||
| Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. | Q33177527 | ||
| Mycophenolate mofetil and its mechanisms of action | Q33957177 | ||
| Mycophenolate mofetil: implications for the treatment of glomerular disease | Q34346741 | ||
| Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro study | Q38525562 | ||
| Effects of mycophenolic acid on endothelial cells | Q40435492 | ||
| Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts | Q42555924 | ||
| Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy | Q43548938 | ||
| Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients | Q43729226 | ||
| Mycophenolate mofetil treatment for primary glomerular diseases | Q43889676 | ||
| Antiproliferative effect of mycophenolate mofetil on cultured human Tenon fibroblasts | Q44033986 | ||
| Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity. | Q44039596 | ||
| Mycophenolic acid antagonizes the activation of cultured human mesangial cells | Q44091653 | ||
| Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes | Q44242781 | ||
| Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. | Q44317211 | ||
| Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome | Q44458286 | ||
| Effect of the peritoneal dialysis prescription on pentosidine in children | Q44536610 | ||
| Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy | Q44662228 | ||
| Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity | Q44663035 | ||
| Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. | Q44741825 | ||
| Effects of commonly used immunosuppressants on graft-derived fibroblasts | Q44898925 | ||
| Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation | Q44940055 | ||
| Effects of mycophenolate mofetil and lisinopril on collagen deposition in unilateral ureteral obstruction in rats | Q45119648 | ||
| Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril | Q46381254 | ||
| Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration | Q46420431 | ||
| Mycophenolate mofetil but not the type of calcineurin inhibitor (cyclosporine vs tacrolimus) influences the intragraft mRNA expression of cytokines in human kidney allograft biopsies by in situ RT-PCR analysis. | Q46452689 | ||
| Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome | Q46488621 | ||
| P304 | page(s) | 25-29 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Clinical Transplantation | Q15754920 |
| P1476 | title | Antifibrotic actions of mycophenolic acid | |
| P478 | volume | 20 Suppl 17 |
| Q38000056 | Advances in the current treatment of autoimmune hepatitis |
| Q33536943 | Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials? |
| Q34409787 | Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial |
| Q38222882 | Current and prospective pharmacotherapy for autoimmune hepatitis |
| Q39051365 | Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of mycophenolic acid |
| Q38051706 | Drug choices in autoimmune hepatitis: part B--Nonsteroids |
| Q34093890 | Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation |
| Q43693945 | Effect of mycophenolic acid on cyclosporin A-induced fibronectin expression in rat mesangial cells |
| Q42910542 | Effect of the inosine 5′-monophosphate dehydrogenase inhibitor BMS-566419 on renal fibrosis in unilateral ureteral obstruction in rats |
| Q33602730 | Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis |
| Q34728886 | Effects of mycophenolate mofetil on kidney function and phosphorylation status of renal proteins in Alport COL4A3-deficient mice |
| Q47890306 | Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome |
| Q38730872 | Evolving paradigm of treatment for autoimmune hepatitis |
| Q37629675 | Hepatic inflammation and progressive liver fibrosis in chronic liver disease |
| Q34168552 | Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients |
| Q34116774 | In rat renal fibroblasts, mycophenolic acid inhibits proliferation and production of the chemokine CCL2, stimulated by tumour necrosis factor-alpha. |
| Q47305480 | Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets. |
| Q36024387 | Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts |
| Q42612170 | Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up |
| Q57791759 | Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C |
| Q36519714 | Medical management of retroperitoneal fibrosis |
| Q37290624 | Mycophenolate mofetil in the treatment of lupus nephritis. |
| Q46540016 | Mycophenolate mofetil: a novel immunosuppressant in the treatment of dystrophic epidermolysis bullosa, a randomized controlled trial |
| Q50485528 | Mycophenolic Acid-Induced Developmental Defects in Zebrafish Embryos. |
| Q35049578 | Mycophenolic acid inhibits migration and invasion of gastric cancer cells via multiple molecular pathways |
| Q47267138 | Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil |
| Q52674866 | Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies. |
| Q36220172 | Prevention of hepatitis C recurrence after liver transplantation: An update |
| Q33394798 | Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study |
| Q38175465 | Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis |
| Q82425088 | The renal benefit of mycophenolate mofetil after liver transplantation |
| Q39042222 | Transcriptomic changes induced by mycophenolic acid in gastric cancer cells |
| Q46948718 | Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome |
Search more.